Apatinib for the treatment of gastric cancer

被引：270

作者：

Geng, Ruixuan ^{[1
]}

Li, Jin ^{[1
]}

机构：

[1] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Med Oncol, Shanghai 200032, Peoples R China

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2015年 / 16卷 / 01期

关键词：

apatinib; stomach neoplasms; tyrosine kinase inhibitor; VEGF receptor-2; RANDOMIZED PHASE-III; SUPPORTIVE CARE; DOUBLE-BLIND; CHEMOTHERAPY PLUS; 1ST-LINE THERAPY; OPEN-LABEL; GROWTH; INHIBITOR; YN968D1; CAPECITABINE;

D O I：

10.1517/14656566.2015.981526

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Introduction: Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib mesylate, a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has been recommended as third-line treatment for metastatic gastric cancer patients. Areas covered: The current review summarizes the publications and conference reports relating to apatinib from preclinical and clinical research in gastric cancer. Apatinib showed good safety, tolerance and treatment efficacy in Phase I/II studies. In a Phase III study, apatinib prolonged the median overall survival of patients with chemotherapy-refractory metastatic gastric cancer by 55 days and the median progression-free survival by 25 days compared with placebo. Expert opinion: Apatinib is a new treatment option for advanced gastric cancer. Apatinib is expected to have a broader application when it has been evaluated worldwide. The key issues are to find biomarkers and overcome drug resistance.

引用

页码：117 / 122

页数：6

共 33 条

[1]

The effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma [J].

Akutsu, Yasunori ;

Qin, Wei ;

Murakami, Kentaro ;

Hoshino, Isamu ;

Hanari, Naoyuki ;

Nishimori, Takanori ;

Mori, Mikito ;

Isozaki, Yuka ;

Toyozumi, Takeshi ;

Hu, Xin ;

Suito, Hiroshi ;

Akanuma, Naoki ;

Takahashi, Masahiko ;

Matsubara, Hisahiro .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)

[2]

Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma [J].

Amedei, Amedeo ;

Munari, Fabio ;

Della Bella, Chiara ;

Niccolai, Elena ;

Benagiano, Marisa ;

Bencini, Lapo ;

Cianchi, Fabio ;

Farsi, Marco ;

Emmi, Giacomo ;

Zanotti, Giuseppe ;

de Bernard, Marina ;

Kundu, Manikuntala ;

D'Elios, Mario Milco .

INTERNAL AND EMERGENCY MEDICINE, 2014, 9 (03) :303-309

[3]

[Anonymous], GASTRIC CANC OFFICIA

[4]

Bang YJ, 2010, LANCET, V376, P1302

[5]

Epidemiology of upper gastrointestinal malignancies [J].

Crew, KD ;

Neugut, AI .

SEMINARS IN ONCOLOGY, 2004, 31 (04) :450-464

[6]

Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].

Cunningham, David ;

Starling, Naureen ;

Rao, Sheela ;

Iveson, Timothy ;

Nicolson, Marianne ;

Coxon, Fareeda ;

Middleton, Gary ;

Daniel, Francis ;

Oates, Jacqueline ;

Norman, Andrew Richard .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46

[7]

Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans [J].

Ding, Juefang ;

Chen, Xiaoyan ;

Gao, Zhiwei ;

Dai, Xiaojian ;

Li, Liang ;

Xie, Cen ;

Jiang, Haoyuan ;

Zhang, Lijia ;

Zhong, Dafang .

DRUG METABOLISM AND DISPOSITION, 2013, 41 (06) :1195-1210

[8]

Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy [J].

Fan, Minhao ;

Zhang, Jian ;

Wang, Zhonghua ;

Wang, Biyun ;

Zhang, Qunlin ;

Zheng, Chunlei ;

Li, Ting ;

Ni, Chen ;

Wu, Zhenhua ;

Shao, Zhimin ;

Hu, Xichun .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (01) :141-151

[9]

ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS [J].

FOLKMAN, J ;

MERLER, E ;

ABERNATHY, C ;

WILLIAMS, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 133 (02) :275-+

[10]

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial [J].

Ford, Hugo E. R. ;

Marshall, Andrea ;

Bridgewater, John A. ;

Janowitz, Tobias ;

Coxon, Fareeda Y. ;

Wadsley, Jonathan ;

Mansoor, Wasat ;

Fyfe, David ;

Madhusudan, Srinivasan ;

Middleton, Gary W. ;

Swinson, Daniel ;

Falk, Stephen ;

Chau, Ian ;

Cunningham, David ;

Kareclas, Paula ;

Cook, Natalie ;

Blazeby, Jane M. ;

Dunn, Janet A. .

LANCET ONCOLOGY, 2014, 15 (01) :78-86

← 1 2 3 4 →